Intelligence Feed event · Policy · 2026-09-13

    Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle

    Question

    Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle

    Direct answer

    Liquidia has established clinical uptake for its dry powder inhaler Yutrepia, logging more than 5,000 patient starts through July 2026 in the pulmonary hypertension market. Despite commercial progress, LQDA equity has pulled back 13.9% in the past month as investors weigh elevated R&D spending and ongoing patent litigation against incumbent United Therapeutics. The legal contest centers on treprostinil formulation patents, representing a key binary catalyst for market share division between Yutrepia and United Therapeutics' Tyvaso franchise.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle”, revision 1, evidence through 2026-09-13. https://marketontology.com/market-events/2026-09-13/liquidia-surpasses-5-000-yutrepia-patient-starts-amid-united-therapeutics-patent-e047c3

    POLICY
    Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle
    Liquidia has established clinical uptake for its dry powder inhaler Yutrepia, logging more than 5,000 patient starts through July 2026 in the pulmonary hypertension market. Despite commercial progress, LQDA equity has pulled back 13.9% in the past month as investors weigh elevated R&D spending and ongoing patent litigation against incumbent United Therapeutics. The legal contest centers on treprostinil formulation patents, representing a key binary catalyst for market share division between Yutrepia and United Therapeutics' Tyvaso franchise.
    LQDAUTHR
    Impact
    67
    SEP 13
    SIG
    80%
    LQDAUTHR
    Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle
    Liquidia has established clinical uptake for its dry powder inhaler Yutrepia, logging more than 5,000 patient starts through July 2026 in the pulmonary hypertension market. Despite commercial progress, LQDA equity has pulled back 13.9% in the past month as investors weigh elevated R&D spending and ongoing patent litigation against incumbent United Therapeutics. The legal contest centers on treprostinil formulation patents, representing a key binary catalyst for market share division between Yutrepia and United Therapeutics' Tyvaso franchise.
    → Yutrepia adoption gains contest United Therapeutics' Tyvaso market share in pulmonary arterial hypertension, while patent dispute outcomes govern LQDA's commercial exclusivity and royalty liabilities.
    Impact
    Liquidia has established clinical uptake for its dry powder inhaler Yutrepia, logging more than 5,000 patient starts through July 2026 in the pulmonary hypertension market. Despite commercial progress, LQDA equity has pulled back 13.9% in the past month as investors weigh elevated R&D spending and ongoing patent litigation against incumbent United Therapeutics. The legal contest centers on treprostinil formulation patents, representing a key binary catalyst for market share division between Yutrepia and United Therapeutics' Tyvaso franchise.
    Affected
    LQDAUTHR
    Transmission
    Yutrepia adoption gains contest United Therapeutics' Tyvaso market share in pulmonary arterial hypertension, while patent dispute outcomes govern LQDA's commercial exclusivity and royalty liabilities.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LQDAcommercial drug uptake versus patent litigation riskMixed1-3mYutrepia exceeded 5,000 patient starts as of July 2026 while LQDA faces ongoing United Therapeutics litigation.
    UTHRPAH market share defense and patent exclusivity enforcementMixed1-3mUnited Therapeutics is in active patent litigation defending treprostinil against Yutrepia.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month